Thymosin Alpha-1 5 mg lyophilised vial
ShippingTracked, dispatched to EU and non-EU
Dispatched same working dayOn orders paid before 2:00 PM
Customs & importRules vary by country — check yours before ordering
Real supportWhatsApp & email

Thymosin Alpha-1 5 mg

N-acetylated 28-residue peptide, residues 2-29 of prothymosin alpha

from €34.95 per unit
Choose variant
Thymosin Alpha-1 1 × €34.95
€34.95
Peptide offer
Shipping tracked
Calculated at checkout
Total before delivery
€34.95

For laboratory research only. Not for human or animal use.
Testing information · Delivery · Returns

Product details

Thymosin Alpha-1 5mg

Thymosin alpha-1 (Ta1) is a single-chain peptide of 28 amino acids, sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, with the alpha-amino group of the N-terminal serine blocked by an acetyl group. The molecular formula of the free peptide is C129H215N33O55 and the average molecular mass is approximately 3108.3 g/mol. It carries CAS registry number 62304-98-7. The synthetic peptide is assigned the international non-proprietary name thymalfasin; PowerfullyPeptides supplies it as a laboratory reagent, not as a medicinal product.

All presented information is based on scientific publications which can be found at the end of product description below.

  1. 1Usage of peptide

    The product is intended for scientific research and development purposes only. Chemical substances shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. Intended only for in-vitro research, such as Receptor-ligand binding studies, Enzyme activity assays, Cell proliferation assays, Cell signaling assays, Epitope mapping, ect.

  2. 2Peptides in transport

    Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.

  3. 3Storage of lyophilized peptides

    Upon receiving the lyophilized peptide, store at 4 °C or colder and away from bright light. Lyophilized peptides are stable at room temperature for weeks, but for longer-term storage, it is safer to store at -20 °C or colder. Exposure to moisture will greatly decrease long-term stability of lyophilized peptides. Before using the peptide, remove from cold storage and allow the peptide to equilibrate to room temperature before removing the lid of the container, in order to reduce the uptake of moisture that is present in the surrounding atmosphere.

  4. 4Storage of peptide solutions

    The shelf life of peptide solutions is limited. Freezing the aliquots will prolong the storage life of the peptide. What is globally accepted for peptides in solution is that they are generally stable for 3 or more weeks at +4°C and for 3-4 months at -20°C. Avoid repeated freeze-thaw cycles, as this can degrade the peptides.

Used solely for in vitro experiments and cannot be:

  • Used in clinical trials involving humans
  • Administered to humans as part of an experiment or investigation
  • Supplied to another party for human investigational use
Related reading
Research & references

Description of Thymosin Alpha-1

Thymosin alpha-1 (Ta1) is a single-chain peptide of 28 amino acids, sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, with the alpha-amino group of the N-terminal serine blocked by an acetyl group. The molecular formula of the free peptide is C129H215N33O55 and the average molecular mass is approximately 3108.3 g/mol. It carries CAS registry number 62304-98-7. The synthetic peptide is assigned the international non-proprietary name thymalfasin; PowerfullyPeptides supplies it as a laboratory reagent, not as a medicinal product.

The peptide was first characterised by Goldstein and colleagues in 1977, who isolated it from thymosin fraction 5, a partially purified extract of calf thymus, and determined its 28-residue sequence, describing it as a heat-stable, highly acidic molecule (Goldstein et al., Proc Natl Acad Sci USA, 1977). Later work established that Ta1 corresponds to residues 2 to 29 of a larger intracellular precursor protein, prothymosin alpha, rather than being an independently transcribed gene product; UniProt annotates exactly this peptide within human prothymosin alpha and records its N-terminal serine as N-acetylserine. Material sold today is not extracted from tissue. It is produced by solid-phase peptide synthesis, and a recombinant route in which N-alpha-acetylated Ta1 is released from recombinant prothymosin alpha by legumain cleavage has also been published (Liu B et al., 2013).

The composition is unusual and accounts for the handling behaviour. The sequence contains no aromatic residues, no cysteine, no glycine and no proline, so the peptide has almost no absorbance at 280 nm and cannot form disulfide bridges. It carries nine acidic side chains (three aspartate, six glutamate) against four lysines, and with the N-terminus acetylated the net charge at neutral pH is strongly negative; reported isoelectric points sit near pH 4. Solution-state structure has been examined by NMR: in 40 percent trifluoroethanol / 60 percent water the peptide was reported to adopt an alpha-helix spanning residues 14 to 26, together with two double beta-turns within the N-terminal twelve residues that form a distorted helical region (Elizondo-Riojas et al., 2011).

Overview of Published Research

The references below provide background literature on Thymosin Alpha-1. They do not describe testing of this product. Consult each publication for its study materials, methods and limitations.

References

  1. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, Lai CY, Chang D, Wang SS, Harvey C, Ramel AH, Meienhofer J. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences USA. 1977;74(2):725-729. doi: 10.1073/pnas.74.2.725 · PubMed
  2. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, Di Francesco P, Garaci E. Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood. 2004;103(11):4232-4239. doi: 10.1182/blood-2003-11-4036 · PubMed
  3. Elizondo-Riojas MA, Chamow SM, Tuthill CW, Gorenstein DG, Volk DE. NMR structure of human thymosin alpha-1. Biochemical and Biophysical Research Communications. 2011;416(3-4):356-361. doi: 10.1016/j.bbrc.2011.11.041 · PubMed
  4. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care. 2013;17(1):R8. doi: 10.1186/cc11932 · PubMed
  5. Liu B, Gong X, Chang S, Sun P, Wu J. Generation of mature N-alpha-terminal acetylated thymosin alpha 1 by cleavage of recombinant prothymosin alpha. The Scientific World Journal. 2013;2013:387282. doi: 10.1155/2013/387282 · PubMed
  6. Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, Liu Y, Chen L, Li M, Wang G, Yuan Z, Diao B, Wu Y, Chen Y. Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells. Clinical Infectious Diseases. 2020;71(16):2150-2157. doi: 10.1093/cid/ciaa630 · PubMed
  7. Wu J, Pei F, Zhou L, Li W, Sun R, Li Y, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. Correction: BMJ. 2025;389:r1098. doi: 10.1136/bmj-2024-082583 · PubMed
  8. Gu B, Zhou Y, Nie Y, et al. Efficacy of thymosin alpha1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology. 2025;15:1673959. doi: 10.3389/fcimb.2025.1673959 · PubMed
Also in stock

Also in stock

All products →
GLP-3-RT research vial
In stock

GLP-3-RT

€88.95

C221H342N46O68
Glow Blend research vial
In stock

Glow Blend

€101.95

GHK-Cu research vial
In stock

GHK-Cu

€34.95

C14H22CuN6O4
MT2 research vial
In stock

MT2

€49.95

C50H69N15O9
NAD+ research vial
In stock

NAD+

€63.95

C21H27N7O14P2